Strathmann
This sponsor has funded 2 studies across 1 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 45869 | Finalised | Not included in RMP | Retrosepctive Analysis of the efficacy and tolerability of pridinol in patients with muscle pain - an analysis of open-label real-world data provided... | No | No |
| 49718 | Finalised | Not included in RMP | Pridinol vs. nsaids - efficacy/tolerability in acute (low) back pain. A propensity-score matched, comparative 2-cohort, 4-week real world evidence... | No | No |
PAS by Risk Management Plan (RMP) requirement
Strathmann
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Strathmann
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Strathmann
1 Study countries specified are the following:
- Germany